Medical-device reimbursement listing
Consultancies that secure CPT/HCPCS billing codes, payer coverage policies and national health-insurance listings for medical devices — turning FDA clearance into an actual reimbursement pathway that determines whether hospitals and clinicians will be paid to use the device.
1 · What it gives
Medical-device reimbursement listing is a B2B services category in which specialist consultancies secure the CPT/HCPCS billing codes, payer coverage policies and national health-insurance listings a medical device needs to be paid for in clinical use — a step distinct from, and often more commercially decisive than, FDA clearance itself. MCRA runs a dedicated regulatory and reimbursement consulting practice supporting medical device companies through both FDA 510(k) submission and CPT/HCPCS coding strategy. Avalere Health integrates clinical, coding and reimbursement strategy from early development, arguing that early-integrated strategies transform market-access challenges into successful launches with clear coverage and payment pathways. Boston Strategic Partners combines business and clinical strategy with health-economics and outcomes research (HEOR) and medical/technical writing to support device reimbursement dossiers. Emergo by UL, a global QA/RA consulting firm, extends its FDA 510(k)/De Novo/PMA regulatory practice into the reimbursement-adjacent compliance work devices need alongside clearance. Real Endpoints is a market-access advisory firm focused specifically on commercial and private-payer coverage policy and prior-authorization navigation for medical devices. Vintura, based in the Netherlands, advises life-sciences clients on policy shaping and commercial strategy across European reimbursement systems, addressing the persistent gap between what a device or medicine can offer and what patients actually receive.
The key directions of medical-device reimbursement listing are:
- CPT/HCPCS coding strategy: securing or navigating the billing codes (Current Procedural Terminology, Healthcare Common Procedure Coding System) a device needs for a provider to bill for its use.
- Payer coverage-policy navigation: working with commercial insurers and public payers to establish a coverage policy under which the device is eligible for payment.
- Health-economics and outcomes research (HEOR): building the clinical and economic evidence dossier payers require to justify a coverage or reimbursement decision.
- European and national reimbursement-system policy shaping: advising on the specific health-technology-assessment and reimbursement-listing processes of individual national systems outside the US.
Sectoral value chain#
[FDA clearance/approval] ──> [CPT/HCPCS coding strategy] ──> [Payer coverage-policy submission]
│
(HEOR evidence-dossier development)
│
[Ongoing coverage-policy monitoring] <──── [Reimbursement decision & listing] <─── [Payer review & negotiation]
Value chain levels#
| Level | Description | Key inputs/outputs |
|---|---|---|
| Regulatory clearance | The device receives FDA clearance or approval, the prerequisite before a reimbursement pathway can be pursued. | In: Regulatory submission. Out: Cleared/approved device. |
| Coding strategy | Determining and securing the CPT/HCPCS billing codes a provider needs to bill for the device’s use. | In: Cleared/approved device, procedure description. Out: Assigned or requested billing code. |
| Coverage-policy submission | Submitting evidence to commercial and public payers to establish a coverage policy for the device. | In: Billing code, clinical evidence. Out: Coverage-policy submission. |
| Payer review and negotiation | Payers review the submission, often requesting additional health-economics evidence before deciding. | In: Coverage-policy submission. Out: Payer review outcome. |
| Reimbursement decision and listing | The payer issues a coverage decision and, where applicable, the device is added to a formal reimbursement listing. | In: Payer review outcome. Out: Coverage decision, reimbursement listing. |
| Ongoing coverage-policy monitoring | Tracking payer coverage-policy changes and prior-authorization requirements that affect the device’s ongoing reimbursement status. | In: Reimbursement listing. Out: Maintained reimbursement status. |
Cross-cutting technologies of the sector:
- CPT/HCPCS coding strategy: the specific process of determining and securing the billing codes a medical device needs for a provider to be paid for its use.
- Payer coverage-policy analytics: structured tracking and analysis of commercial and public payer coverage policies relevant to a specific device category.
- Market-access consulting: integrated advisory services combining regulatory, coding, coverage and HEOR expertise to build a full reimbursement pathway.
2 · What it replaces 2 · matched by industry
| D2E4 | Crop disease forecasting models, spore traps, pheromone and smart pest traps and field diagnostics — spray when risk is real instead of calendar-based fungicide and insecticide programmes Replaces: Fixed-interval ("calendar") protective fungicide sprays and routine insecticide applications regardless of pest pressure | EAC |
| D2E– | On-farm culture, PCR panels, rapid tests and veterinary laboratory services for livestock and aquaculture — treat what is diagnosed instead of blanket and prophylactic antibiotic treatment Replaces: Blanket treatment of every clinical mastitis case, group metaphylaxis on suspicion, prophylactic antibiotics in hatcheries and ponds, … | DIAG |
3 · How to implement 6 steps
- 1Regulatory clearanceRegulatory & certificationThe device receives FDA clearance or approval, the prerequisite step before a reimbursement pathway can be pursued.Registration in Russia / EAEU: EAC — EAEU accredited bodies / Rosakkreditatsiya
- 2CPT/HCPCS coding strategyThe consultancy determines and secures the billing codes a provider needs to bill for the device’s use, requesting a new code where none exists.
- 3Coverage-policy submissionEvidence supporting the device’s clinical and economic value is submitted to commercial and public payers to establish a formal coverage policy.
- 4Payer review and negotiationPayers review the submission, often requesting additional health-economics evidence or negotiating specific coverage terms before deciding.
- 5Reimbursement decision and listingThe payer issues a coverage decision, and where applicable, the device is added to a formal reimbursement listing that providers can bill against.
- 6Ongoing coverage-policy monitoringThe consultancy tracks payer coverage-policy changes and prior-authorization requirements that could affect the device’s ongoing reimbursement status.
4 · Who delivers
Matched suppliers (matched automatically)
| Boston Scientific | United States | Producer | active |
| Giant Biogene Holding | China | Distributor | active |
| Kaneka | Japan | Producer | active |
| Saber Chemical, Inc. | United States | Producer | active |
| EcoWin (Dong-A ST sub) | South Korea | Research / RTO | active |
| Daicel | Japan | Producer | active |
| Tsingke Biotechnology | China | Producer | active |
| China Resources Pharmaceutical | Hong Kong | Producer | active |
| Longevity Center Europe | Poland | Services / consulting | active |
| BioYome | Israel | Producer | active |
In the services and supply catalogue 2 · paid service
Consulting & market access · Regulatory & certification
Leading companies and institutes (from the brief)
| Company / Institute | Country | Key products / platforms | Tech features | Status 2026 |
|---|---|---|---|---|
| MCRA | 🇺🇸 USA | Regulatory + reimbursement consulting | Combined FDA 510(k) and CPT/HCPCS practice | commercial |
| Avalere Health | 🇺🇸 USA | Integrated market-access advisory | Clinical/coding/reimbursement strategy | commercial |
| Boston Strategic Partners | 🇺🇸 USA | Business & clinical strategy | HEOR and medical/technical writing | commercial |
| Emergo by UL | 🇺🇸 USA | Global QA/RA consulting | FDA 510(k)/De Novo/PMA-adjacent reimbursement work | commercial |
| Real Endpoints | 🇺🇸 USA | Payer-coverage advisory | Commercial/private-payer coverage focus | commercial |
| Vintura | 🇳🇱 Netherlands | European market-access consulting | Policy shaping across EU reimbursement systems | commercial |
5 · Rules & route to market
declaration registered within 3 working days (testing extra); certification longer
Information, not legal advice — confirm the procedure for your product. (2026-10-06)
United States
The United States hosts the largest concentration of medical-device reimbursement consultancies, several combining FDA regulatory practices with dedicated coding and payer-coverage expertise.
MCRA’s combined regulatory-reimbursement practice, Avalere’s integrated coding strategy, Boston Strategic Partners’ HEOR support, Emergo by UL’s global QA/RA-adjacent work, Real Endpoints’ payer-coverage focus#
- MCRA: runs a dedicated regulatory and reimbursement consulting practice supporting medical device companies through both FDA 510(k) submission and CPT/HCPCS coding strategy.
- Avalere Health: integrates clinical, coding and reimbursement strategy from early development, transforming market-access challenges into launches with clear coverage and payment pathways.
- Boston Strategic Partners: combines business and clinical strategy with health-economics and outcomes research and medical/technical writing to support device reimbursement dossiers.
- Emergo by UL: a global QA/RA consulting firm extending its FDA 510(k)/De Novo/PMA regulatory practice into the reimbursement-adjacent compliance work devices need alongside clearance.
- Real Endpoints: a market-access advisory firm focused specifically on commercial and private-payer coverage policy and prior-authorization navigation for medical devices.
European Union
Europe hosts market-access and policy-shaping consultancies working across the fragmented national health-technology-assessment and reimbursement-listing systems of individual EU member states.
Vintura’s policy-shaping and commercial-strategy practice across European reimbursement systems#
- Vintura: based in the Netherlands, advises life-sciences clients on policy shaping and commercial strategy across European reimbursement systems, addressing the persistent gap between what a device can offer and what patients actually receive under national coverage decisions.
China
China is covered qualitatively rather than through a live-screened Chinese vendor: candidate Chinese medical-device reimbursement consultancies searched during this screen returned no confirming 2026 source, so no Chinese company is tabled below. Medical-device reimbursement listing in China runs through the National Healthcare Security Administration’s centralized procurement and medical-insurance catalog processes rather than the payer-by-payer model common in the US and Europe, and specialist consulting practices supporting this process could not be confirmed in this screen.
China’s centralized medical-insurance listing process without a confirmed specialist consultancy#
- Centralized listing model: device reimbursement in China runs through the National Healthcare Security Administration’s centralized procurement and medical-insurance catalog listing process, structurally distinct from the multi-payer US model.
- Domestic gap: no Chinese-headquartered medical-device reimbursement consultancy confirmed by a live 2026 source was found during this screen.
6 · Money: tenders & grants
| Grant | DOD Defense Health Agency (DHA) Research & Development FY23-FY27 BROAD AGENCY ANNOUNCEMENT for Extramural … Defense Health Agency Contracting Activity - DHACA · United States | Sep 30, 2027 311 days |
| Grant | Strengthening evidence-based policies for the resilience of European agriculture and forestry and related … European Commission · EU | Sep 23, 2027 304 days |
| Grant | Strengthening strategic advice and synergies between EU and national Research and Innovation agendas and … European Commission · EU | May 11, 2027 169 days |
7 · Tech stack & innovations
The medical-device reimbursement listing stack combines regulatory-adjacent coding expertise with structured payer-coverage analytics and health-economics evidence development:
- CPT/HCPCS coding strategy:
- Firms such as MCRA and Avalere Health determine and secure the specific billing codes a device needs, a step that directly determines whether providers can be paid for using it.
- Payer coverage-policy analytics:
- Real Endpoints specializes in tracking and navigating commercial and private-payer coverage policy and prior-authorization requirements specific to a device category.
- HEOR evidence development:
- Boston Strategic Partners builds the health-economics and outcomes research evidence dossier payers require to justify a coverage or reimbursement decision.
Sources 7 · 0 independent · 7 producer sites
Producers' own sites 7
- Mcra producer checked 2026-07-27 · link not kept
- Avalere health producer checked 2026-05-12 · link not kept
- Boston strategic partners producer checked 2026-06-12 · link not kept
- Emergo by ul producer checked 2026-06-02 · link not kept
- Real endpoints producer checked 2026-07-30 · link not kept
- Health advances producer checked 2026-06-15 · link not kept
- Vintura producer checked 2026-05-29 · link not kept